Recombinant Human Soluble RANK Ligand

RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.¹ RANKL is essential for osteoclast formation, activation, and survival.² RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.³ RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.⁴

The biological activity of Human sRANKL was determined by its ability to induce osteoclast differentiation on mouse splenocytes. The expected ED₅₀= 5-15 ng/ml in the presence of 2.5 µg/ml of the cross-linking antibody, PN:P246.

Histidine Tag

AAC51762

mhhhhhhhhh hgggsgggsg ggsiegrgsq hiraekamvd gswldlakrs kleaqpfahl tinatdipsg shkvslsswy hdrgwgkisn mtfsngkliv nqdgfyylya nicfrhhets gdlateylql mvyvtktsik ipsshtlmkg gstkywsgns efhfysinvg gffklrsgee isievsnpsl ldpdqdatyf gafkvrdid

Met

Lyophilized

The predicted molecular weight of Recombinant Human sRANKL is Mr 23 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 35 kDa.

23

This recombinant protein was 0.2 µm filtered and lyophilized from 20 mM MOPS and 500 mM NaCL, pH 6.5 with 5% trehalose.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Takayanagi, H. et al. (2003) Arthritis Res Ther. 5: 20
2. Kostenuik, PJ. et al. (2005) Endocrinology 146: 3235
3. Holven ,KB. et al. (2009) Stroke 40: 241
4. Penninger, JM. et al. (2008) Ann N Y Acad Sci. 1143: 123